Breaking: Moderna & Merck mRNA Melanoma Vaccine Succeeds in Phase 3
What if a cancer vaccine could be manufactured specifically for your tumor?Intismeran is an individualized mRNA cancer therapy designed from the mutations found inside a patient's own cancer. Combined with pembrolizumab (Keytruda), it has now reached an important Phase 3 milestone in patients with high-risk melanoma.
In this lecture, we’ll explore the fascinating immunology behind this approach: how tumor mutations become neoantigens, how an mRNA vaccine can direct CD4+ and CD8+ T-cell responses, why cancer may escape those same T cells naturally, and why checkpoint inhibition may make the difference.
And, importantly, we’ll separate what the new results actually show from what we still do not know.
Connect with Dr. Been
💙 Want to support this work?
Get access to my medical courses: https://www.drbeen.com
☕ Buy me a coffee: https://www.buymeacoffee.com/DrMobeenSyed
🎥 Become a patron: https://www.patreon.com/mobeensyed?fan_landing=true
💵 PayPal: https://paypal.me/mobeensyed?locale.x=en_US
📬 My Substack: https://mobeensyedmd.substack.com/
🛑 Medical Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health-related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.
Dr. Mobeen Syed serves as a consultant with the CDC. The opinions and views expressed in this lecture are his own and do not necessarily represent the views of the CDC, HHS, or the United States Government.
Keywords
intismeran, intismeran autogene, V940, mRNA-4157, cancer vaccine, personalized cancer vaccine, mRNA cancer vaccine, melanoma vaccine, melanoma treatment, pembrolizumab, Keytruda, neoantigen, neoantigens, tumor neoantigens, personalized medicine, precision oncology, cancer immunotherapy, immunotherapy, CD8 T cells, cytotoxic T cells, CD4 T cells, helper T cells, PD-1, PD-L1, checkpoint inhibitor, immune checkpoint blockade, dendritic cells, MHC class I, MHC class II, tumor mutations, cancer immunity, melanoma immunotherapy, Moderna cancer vaccine, Merck cancer vaccine, personalized neoantigen therapy, DrBeen, Dr Mobeen Syed
URL list from Wednesday, Aug. 19 2026 22:46 PM
Courses | DrBeen
https://www.drbeen.com/
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma - Merck.com
https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/
Study Details | NCT05933577 | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | ClinicalTrials.gov
https://clinicaltrials.gov/study/NCT05933577
iCloud Notes
https://www.icloud.com/notes/note/UHJpdmF0ZTo6Tm90ZXM6OmN1cnJlbnRVc2VyOjoxYzgyMTkxNi0yZTZmLTRiNzAtYjEzOC1jZDg2MGJiYjBiZDc=?id=123 Receive SMS online on sms24.me
TubeReader video aggregator is a website that collects and organizes online videos from the YouTube source. Video aggregation is done for different purposes, and TubeReader take different approaches to achieve their purpose.
Our try to collect videos of high quality or interest for visitors to view; the collection may be made by editors or may be based on community votes.
Another method is to base the collection on those videos most viewed, either at the aggregator site or at various popular video hosting sites.
TubeReader site exists to allow users to collect their own sets of videos, for personal use as well as for browsing and viewing by others; TubeReader can develop online communities around video sharing.
Our site allow users to create a personalized video playlist, for personal use as well as for browsing and viewing by others.
@YouTubeReaderBot allows you to subscribe to Youtube channels.
By using @YouTubeReaderBot Bot you agree with YouTube Terms of Service.
Use the @YouTubeReaderBot telegram bot to be the first to be notified when new videos are released on your favorite channels.
Look for new videos or channels and share them with your friends.
You can start using our bot from this video, subscribe now to Breaking: Moderna & Merck mRNA Melanoma Vaccine Succeeds in Phase 3
What is YouTube?
YouTube is a free video sharing website that makes it easy to watch online videos. You can even create and upload your own videos to share with others. Originally created in 2005, YouTube is now one of the most popular sites on the Web, with visitors watching around 6 billion hours of video every month.
